Realta Investment Advisors Has $1.19 Million Stock Position in Axon Enterprise, Inc (NASDAQ:AXON)

Realta Investment Advisors increased its stake in Axon Enterprise, Inc (NASDAQ:AXON - Free Report) by 27.6% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,265 shares of the biotechnology company's stock after acquiring an additional 490 shares during the quarter. Realta Investment Advisors' holdings in Axon Enterprise were worth $1,191,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Xponance Inc. increased its holdings in Axon Enterprise by 2.9% in the first quarter. Xponance Inc. now owns 16,939 shares of the biotechnology company's stock worth $8,909,000 after purchasing an additional 470 shares in the last quarter. Kesler Norman & Wride LLC bought a new stake in Axon Enterprise in the first quarter worth approximately $275,000. Fidelis Capital Partners LLC increased its holdings in Axon Enterprise by 15.9% in the first quarter. Fidelis Capital Partners LLC now owns 619 shares of the biotechnology company's stock worth $326,000 after purchasing an additional 85 shares in the last quarter. Bosman Wealth Management LLC bought a new stake in Axon Enterprise in the first quarter worth approximately $2,846,000. Finally, DMC Group LLC increased its holdings in Axon Enterprise by 2.6% in the first quarter. DMC Group LLC now owns 1,018 shares of the biotechnology company's stock worth $535,000 after purchasing an additional 26 shares in the last quarter. 79.08% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Axon Enterprise

In other news, CRO Cameron Brooks sold 3,000 shares of the stock in a transaction dated Friday, May 30th. The shares were sold at an average price of $740.76, for a total value of $2,222,280.00. Following the sale, the executive directly owned 19,447 shares of the company's stock, valued at approximately $14,405,559.72. This represents a 13.36% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Brittany Bagley sold 3,400 shares of the stock in a transaction dated Tuesday, May 13th. The stock was sold at an average price of $700.00, for a total transaction of $2,380,000.00. Following the completion of the sale, the chief financial officer directly owned 131,833 shares in the company, valued at approximately $92,283,100. The trade was a 2.51% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 44,642 shares of company stock valued at $30,500,428. 4.40% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

AXON has been the subject of several recent research reports. The Goldman Sachs Group boosted their price objective on Axon Enterprise from $730.00 to $830.00 and gave the company a "buy" rating in a report on Wednesday, May 14th. Bank of America boosted their price objective on Axon Enterprise from $750.00 to $895.00 and gave the company a "buy" rating in a report on Wednesday, June 4th. Needham & Company LLC boosted their price objective on Axon Enterprise from $600.00 to $750.00 and gave the company a "buy" rating in a report on Thursday, May 8th. Barclays boosted their price objective on Axon Enterprise from $726.00 to $735.00 and gave the company an "overweight" rating in a report on Friday, May 9th. Finally, Wolfe Research began coverage on Axon Enterprise in a report on Monday. They set an "outperform" rating for the company. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eleven have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $699.55.

Axon Enterprise Price Performance

AXON opened at $729.62 on Friday. The company has a market capitalization of $56.80 billion, a price-to-earnings ratio of 176.24, a PEG ratio of 84.37 and a beta of 1.29. The company has a quick ratio of 2.62, a current ratio of 2.83 and a debt-to-equity ratio of 0.68. The firm has a 50-day moving average price of $752.67 and a 200-day moving average price of $640.95. Axon Enterprise, Inc has a twelve month low of $279.02 and a twelve month high of $830.21.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last posted its earnings results on Wednesday, May 7th. The biotechnology company reported $1.41 earnings per share for the quarter, topping the consensus estimate of $1.34 by $0.07. The firm had revenue of $603.63 million during the quarter, compared to the consensus estimate of $585.67 million. Axon Enterprise had a net margin of 14.86% and a return on equity of 5.81%. The company's revenue was up 31.3% on a year-over-year basis. During the same quarter last year, the company earned $1.15 earnings per share. Equities analysts expect that Axon Enterprise, Inc will post 5.8 EPS for the current year.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.